OpportunityTitle: Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research  SBIR [R43/R44]
Description: Purpose. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) issues this Funding Opportunity Announcement (FOA) to solicit Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to accelerate translation and/or commercialization of musculoskeletal and skin tissue engineering and regenerative medicine research. The focus of this FOA is on pre-clinical studies with potential to immediately lead to phase I human clinical trials, or on development of pre-clinical animal models to assess safety and efficacy of potential commercial products in musculoskeletal and skin tissue engineering and regenerative medicine. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I and Phase II. This FOA does not support Fast Track applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 3-5 projects awarded as a result of this announcement is $1.5 million total costs for fiscal year 2010. Future year amounts will depend on annual appropriations.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;